Prostate cancer screening; is this a teachable moment?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Are treatments for cervical precancerous lesions in less-developed countries safe enough to promote scaling-up of cervical screening programs? A systematic review.BMC women's health · 2010
   Pooled it
2. Meeting the global demands of epidemiologic transition - the indispensable role of cancer prevention.Molecular oncology · 2013
   Review
3. African American men significantly underestimate their risk of having prostate cancer at the time of biopsy.Psycho-oncology · 2013
   Article
4. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.The journals of gerontology. Series A, Biological sciences and medical sciences · 2013
   Article
5. Factors influencing men's decisions regarding prostate cancer screening: a qualitative study.Journal of community health · 2011
   Article
6. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.European journal of nuclear medicine and molecular imaging · 2011
   Article
7. High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S).Molecular cancer therapeutics · 2011
   Article

Corrections and comments

• Comment on
  Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.2009

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as